EMN 2021 | Treating young patients with myeloma
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, gives an overview of the current treatment landscape for young patients with myeloma. Prof. Cavo discusses how autologous stem cell transplantation remains the standard-of-care for newly diagnosed myeloma patients. The aim of transplantation, consolidation, and maintenance, is to achieve and sustain measurable residual disease (MRD)-negativity. Bortezomib, thalidomide and dexamethasone (VTd) is used as induction therapy. Recently, daratumumab plus VTd induction therapy has been approved for patients with newly diagnosed multiple myeloma by the European Medicines Agency (EMA). Finally, Prof. Cavo highlights two trials demonstrating the superiority of upfront transplantation in comparison to standard dose bortezomib intensification therapy, the IFM/DFCI2009 (NCT01191060) trial and the EMN02/HO95 trial (NCT01208766). This interview took place during the 2021 European Myeloma Network (EMN) congress.
